TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The webinar will be moderated by Cybin’s Chief Executive Officer Doug Drysdale and will feature two leading experts for a discussion on the psychedelics landscape and current and emerging psychedelic-based therapeutics. Dr. John Krystal, the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital, will be included in the discussion. Also featured will be Dr. David Nutt, DM, FRCP, FRCPsych, FMedSci, DLaws, the Edmund J. Safra Professor of Neuropsychopharmacology, Head Centre for Psychedelic Research in the Division of Brain Sciences, Imperial College London. Interested parties should visit https://ibn.fm/EkkdK to register for the event and access the webcast. In addition, the archived version of the webcast will be available on the company’s investor relations website.

To view the full press release, visit https://ibn.fm/z2ops

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork